We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
National Diabetes Audit Report 1 Care Processes and Treatment Targets 2017-18Audit
- Publication Date:
- 8 Nov 2018
- Geographic Coverage:
- England, Wales
- Geographical Granularity:
- Clinical Commissioning Groups, Local Authorities, GP practices, Hospital Trusts
- Date Range:
- 01 Jan 2017 to 31 Mar 2018
The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK.
The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes.
This short report details the top level findings for the 2017-18 audit. The audit collected data during May and June 2018, for the period 01 January 2017 to 31 March 2018. The top level findings, along with supporting data at Clinical Commissioning Group (CCG), Local Health Board (LHB), GP practice and specialist diabetes service have been made available to provide data back to services in a timely manner that can help drive improvements in the quality of diabetes care locally.
The next report will contain full key findings, recommendations and results of initial analyses into cardiovascular risk reduction and the use of statins. We will communicate to users when the date for this report has been finalised.